bullish
Legend Biotech (传奇生物) Pre-IPO: A Good Deal for the Promising CAR-T
345 Views01 Jun 2020 14:59
Legend Biotech, a subsidiary of Hong Kong-listed GenScript, started book building to raise up to USD 368 million via an IPO. The company has a...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
- Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction26 Jul 2022
- Legend Biotech (传奇生物) Follow-On Offering - Untimely Raise15 Dec 2021
- Legend Biotech (传奇生物) IPO Trading: +27% Upside from Pricing05 Jun 2020
- Legend Biotech (传奇生物) Pre-IPO: A Good Deal for the Promising CAR-T01 Jun 2020
- Legend Biotech (传奇生物) Pre-IPO: Superior Efficacy Vs Bluebird/BMS Candidate26 May 2020
- Legend Biotech (传奇生物) Pre-IPO: All-Stars Except for the Small Indication19 May 2020
x